Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$7.60 USD
+0.44 (6.15%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $7.59 -0.01 (-0.13%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCUL 7.60 +0.44(6.15%)
Will OCUL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCUL
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
Can VAALCO (EGY) Deliver Strong Q4 Earnings Performance?
Other News for OCUL
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Piper Sandler Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)
Investor Day Slides
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), TransMedics Group (TMDX)